Key Points
- Adar1 Capital Management bought 10,200 more Rallybio shares on May 19 at $13.98 each, bringing its direct stake to 926,352 shares worth about $12.95 million.
- The firm has been actively accumulating shares over several recent trading days, including large purchases on May 4, May 5, May 11, and May 13.
- Rallybio recently reported a Q1 loss wider than expected, posting EPS of -$1.46 versus the -$1.20 estimate, while analysts currently rate the stock a consensus Sell.
Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc bought 6,009 shares of the firm's stock in a transaction that occurred on Monday, May 18th. The stock was purchased at an average cost of $13.98 per share, with a total value of $84,005.82. Following the completion of the transaction, the insider directly owned 916,152 shares in the company, valued at $12,807,804.96. This represents a 0.66% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Tuesday, May 19th, Adar1 Capital Management, Llc bought 10,200 shares of Rallybio stock. The stock was purchased at an average cost of $13.98 per share, with a total value of $142,596.00.
- On Friday, May 15th, Adar1 Capital Management, Llc bought 300 shares of Rallybio stock. The stock was purchased at an average cost of $13.90 per share, with a total value of $4,170.00.
- On Wednesday, May 13th, Adar1 Capital Management, Llc bought 79,259 shares of Rallybio stock. The stock was purchased at an average cost of $13.99 per share, with a total value of $1,108,833.41.
- On Tuesday, May 12th, Adar1 Capital Management, Llc bought 800 shares of Rallybio stock. The stock was acquired at an average price of $13.83 per share, for a total transaction of $11,064.00.
- On Monday, May 11th, Adar1 Capital Management, Llc bought 50,000 shares of Rallybio stock. The stock was acquired at an average price of $14.00 per share, for a total transaction of $700,000.00.
- On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The stock was acquired at an average price of $14.00 per share, for a total transaction of $491,414.00.
- On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The stock was acquired at an average price of $13.97 per share, for a total transaction of $1,687,631.88.
Rallybio Price Performance
RLYB opened at $14.58 on Thursday. Rallybio Corporation has a fifty-two week low of $2.16 and a fifty-two week high of $15.31. The firm has a market capitalization of $77.27 million, a PE ratio of -3.20 and a beta of -1.10. The company's 50-day moving average is $10.05 and its 200 day moving average is $7.25.
Rallybio (NASDAQ:RLYB - Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Rallybio to a "hold" rating in a report on Saturday, March 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Rallybio in a report on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of "Sell".
View Our Latest Report on Rallybio
Institutional Investors Weigh In On Rallybio
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd increased its stake in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. Susquehanna International Group LLP increased its stake in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Geode Capital Management LLC increased its stake in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Citadel Advisors LLC increased its stake in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company's stock.
About Rallybio
(
Get Free Report)
Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.
Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
